Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23008Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:29:58Z | - |
| dc.date.available | 2015-11-24T19:29:58Z | - |
| dc.identifier.issn | 1473-4877 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23008 | - |
| dc.rights | Default Licence | - |
| dc.subject | Allylamine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use | en |
| dc.subject | Anticholesteremic Agents/adverse effects/pharmacology/*therapeutic use | en |
| dc.subject | Apolipoproteins B/metabolism | en |
| dc.subject | Azetidines/therapeutic use | en |
| dc.subject | Bile Acids and Salts/*metabolism | en |
| dc.subject | Cholesterol, LDL/drug effects | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Fenofibrate/therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | en |
| dc.subject | Risk Factors | en |
| dc.title | Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1185/030079908X280446 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18291066 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1185/030079908X280446 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | OBJECTIVE: Hypercholesterolaemia is a major risk factor for atherosclerosis and coronary heart disease. Treatment with lipid lowering agents reduces the risk of vascular events. Colesevelam is a novel bile acid sequestrant (BAS) indicated for the treatment of hypercholesterolaemia, either as monotherapy or in combination with statins. SCOPE: This article reviews the efficacy, tolerability and safety of colesevelam in clinical practice. The literature search was based on a PubMed search up to January 2008. FINDINGS: Colesevelam, used alone or in combination with other hypolipidaemic agents (statins, ezetimibe and fenofibrate), has an overall favourable effect on lipid profile. Specifically, colesevelam reduces total and low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B levels and increases high-density lipoprotein cholesterol and apolipoprotein AI. However, colesevelam may slightly raise triglyceride levels. Colesevelam can improve glycaemic control in diabetic patients. Moreover, it may have anti-inflammatory properties, as it can reduce high sensitivity C-reactive protein concentration. Colesevelam almost lacks the intense side effects of previously used BASs, thus resulting in better patient compliance. However, the dose regimen consisting of up to 7 tablets/day and high cost may limit its use. CONCLUSIONS: Colesevelam is a safe alternative for those intolerant to other lipid lowering medication. This BAS also provides an option for patients who do not reach their LDL-C goal despite treatment with a statin. | en |
| heal.journalName | Current Medical Research and Opinion | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
